Assessment of the bystander effect of low dose gamma radiation on rats’ bone marrow

2020 ◽  
Vol 58 (1) ◽  
pp. 33-41
Keyword(s):  
Bone Marrow ◽  
Gamma Radiation ◽  
Low Dose ◽  
Bystander Effect

scholarly journals Immunomodulatory Effect of Green Tea Treatment in Combination with Low-dose Chemotherapy in Elderly Acute Myeloid Leukemia Patients with Myelodysplasia-related Changes

2021 ◽  
Vol 20 ◽  
pp. 153473542110026
Author(s):  
Andrana K. Calgarotto ◽  
Ana L. Longhini ◽  
Fernando V. Pericole de Souza ◽  
Adriana S. Santos Duarte ◽  
Karla P. Ferro ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Acute Myeloid Leukemia ◽  
T Cell ◽  
Green Tea ◽  
Regulatory T Cell ◽  
Myeloid Leukemia ◽  
Low Dose ◽  
Related Factor ◽  
Low Dose Chemotherapy ◽  
Acute Myeloid

Green tea (GT) treatment was evaluated for its effect on the immune and antineoplastic response of elderly acute myeloid leukemia patients with myelodysplasia-related changes (AML-MRC) who are ineligible for aggressive chemotherapy and bone marrow transplants. The eligible patients enrolled in the study (n = 10) received oral doses of GT extract (1000 mg/day) alone or combined with low-dose cytarabine chemotherapy for at least 6 months and/or until progression. Bone marrow (BM) and peripheral blood (PB) were evaluated monthly. Median survival was increased as compared to the control cohort, though not statistically different. Interestingly, improvements in the immunological profile of patients were found. After 30 days, an activated and cytotoxic phenotype was detected: GT increased total and naïve/effector CD8+ T cells, perforin+/granzyme B+ natural killer cells, monocytes, and classical monocytes with increased reactive oxygen species (ROS) production. A reduction in the immunosuppressive profile was also observed: GT reduced TGF-β and IL-4 expression, and decreased regulatory T cell and CXCR4+ regulatory T cell frequencies. ROS levels and CXCR4 expression were reduced in bone marrow CD34+ cells, as well as nuclear factor erythroid 2–related factor 2 (NRF2) and hypoxia-inducible factor 1α (HIF-1α) expression in biopsies. Immune modulation induced by GT appears to occur, regardless of tumor burden, as soon as 30 days after intake and is maintained for up to 180 days, even in the presence of low-dose chemotherapy. This pilot study highlights that GT extracts are safe and could improve the immune system of elderly AML-MRC patients.

scholarly journals Exposure to Low-Dose 56Fe-Ion Radiation Induces Long-Term Epigenetic Alterations in Mouse Bone Marrow Hematopoietic Progenitor and Stem Cells

2014 ◽  
Vol 182 (1) ◽  
pp. 92 ◽  
Author(s):  
Isabelle R. Miousse ◽  
Lijian Shao ◽  
Jianhui Chang ◽  
Wei Feng ◽  
Yingying Wang ◽  
...  
Keyword(s):  
Stem Cells ◽  
Bone Marrow ◽  
Low Dose ◽  
Mouse Bone Marrow ◽  
Epigenetic Alterations ◽  
Hematopoietic Progenitor

scholarly journals Amifostine ameliorates recognition memory defect in acute radiation syndrome caused by relatively low-dose of gamma radiation

2010 ◽  
Vol 11 (1) ◽  
pp. 81 ◽  
Author(s):  
Hae-June Lee ◽  
Joong-Sun Kim ◽  
Myoung-Sub Song ◽  
Heung-Sik Seo ◽  
Miyoung Yang ◽  
...  
Keyword(s):  
Recognition Memory ◽  
Gamma Radiation ◽  
Low Dose ◽  
Acute Radiation ◽  
Acute Radiation Syndrome

scholarly journals Low-Dose Radiotherapy Has No Harmful Effects on Key Cells of Healthy Non-Inflamed Joints

2018 ◽  
Vol 19 (10) ◽  
pp. 3197 ◽  
Author(s):  
Lisa Deloch ◽  
Michael Rückert ◽  
Rainer Fietkau ◽  
Benjamin Frey ◽  
Udo Gaipl
Keyword(s):  
Bone Marrow ◽  
Cell Death ◽  
Low Dose ◽  
Immune Cell ◽  
Bone Marrow Cells ◽  
Positive Impact ◽  
Bone Destruction ◽  
T Cell Subsets ◽  
Low Dose Radiotherapy ◽  
Harmful Effects

Low-dose radiotherapy (LD-RT) for benign inflammatory and/or bone destructive diseases has been used long. Therefore, mechanistic investigations on cells being present in joints are mostly made in an inflammatory setting. This raises the question whether similar effects of LD-RT are also seen in healthy tissue and thus might cause possible harmful effects. We performed examinations on the functionality and phenotype of key cells within the joint, namely on fibroblast-like synoviocytes (FLS), osteoclasts and osteoblasts, as well as on immune cells. Low doses of ionizing radiation showed only a minor impact on cytokine release by healthy FLS as well as on molecules involved in cartilage and bone destruction and had no significant impact on cell death and migration properties. The bone resorbing abilities of healthy osteoclasts was slightly reduced following LD-RT and a positive impact on bone formation of healthy osteoblasts was observed after in particular exposure to 0.5 Gray (Gy). Cell death rates of bone-marrow cells were only marginally increased and immune cell composition of the bone marrow showed a slight shift from CD8+ to CD4+ T cell subsets. Taken together, our results indicate that LD-RT with particularly a single dose of 0.5 Gy has no harmful effects on cells of healthy joints.

scholarly journals Изменение характеристик переизлучающих волокон Y-11 и O-2 под действием гамма облучения

2020 ◽  
Vol 128 (12) ◽  
pp. 1973
Author(s):  
А.Ю. Афанасьев ◽  
А.Ю. Бояринцев ◽  
И.А. Голутвин ◽  
Э.М. Ибрагимова ◽  
А.И. Малахов ◽  
...  
Keyword(s):  
Gamma Radiation ◽  
Dose Rate ◽  
Room Temperature ◽  
Low Dose ◽  
Low Dose Rate ◽  
60Co Gamma ◽  
60Co Gamma Radiation

The effect of 60Co gamma radiation on the intensity of the reemitted light at the exit from WLS-fibers of Y-11 M and O-2 M type WLS fibers and the subsequent restoration of the characteristics of irradiated fibers after exposure to room temperature are investigated. Irradiation of a low dose rate (0.048 Mrad / h) to a dose of 1 Mrad leads to a slight decrease in the intensity of the reemitted light at the exit of both types of fibers, and with a further increase in the dose, the curve does not change. When irradiated with a dose rate of 0.158 Mrad / h, the characteristics of both types of fibers deteriorate significantly. When the irradiated samples are held at room temperature, fiber characteristics are restored.

scholarly journals Phase I Trial of Intra-arterial Administration of Autologous Bone Marrow-Derived Mesenchymal Stem Cells in Patients with Multiple System Atrophy

2021 ◽  
Vol 2021 ◽  
pp. 1-10
Author(s):  
Seok Jong Chung ◽  
Tae Yong Lee ◽  
Yang Hyun Lee ◽  
KyoungWon Baik ◽  
Jin Ho Jung ◽  
...  
Keyword(s):  
Stem Cells ◽  
Bone Marrow ◽  
Mesenchymal Stem Cells ◽  
Multiple System Atrophy ◽  
Phase I ◽  
Dose Group ◽  
Low Dose ◽  
Autologous Bone Marrow ◽  
High Dose ◽  
Autologous Bone

Background. This study is aimed at investigating the safety and tolerability of the intra-arterial administration of autologous bone marrow-derived mesenchymal stem cells (BM-MSCs) in patients with multiple system atrophy- (MSA-) cerebellar type (MSA-C). Methods. This was a single-center, open-label phase I clinical trial in patients with MSA-C. A three-stage dose escalation scheme (low-dose, 3.0 × 10 5 cells/kg; medium-dose, 6.0 × 10 5 cells/kg; high-dose, 9.0 × 10 5 cells/kg) was applied to determine the maximum tolerated dose of intra-arterial administration of BM-MSCs based on the no-observed-adverse-effect level derived from the toxicity study. The occurrence of adverse events was evaluated 1 day before and 1, 14, and 28 days after BM-MSC therapy. Additionally, we assessed changes in the Unified MSA Rating Scale (UMSARS) score 3 months after BM-MSC treatment. Results. One serious adverse drug reaction (ADR) of leptomeningeal enhancement following the intra-arterial BM-MSC administration occurred in one patient in the low-dose group. The safety review of the Internal Monitoring Committee interpreted this as radiological evidence of the blood-brain barrier permeability for MSCs. No other ADRs were observed in the medium- or high-dose groups. In particular, no ischemic lesions on diffusion-weighted images were observed in any of the study participants. Additionally, the medium- and high-dose groups tended to show a slower increase in UMSARS scores than the low-dose group during the 3-month follow-up. Conclusion. The present study confirmed that a single intra-arterial administration of autologous BM-MSCs is a safe and promising neuroprotective strategy in patients with MSA-C.

Sign in / Sign up

Export Citation Format

Share Document